Sono-Tek: The Record Order That Won't Ship Until FY28
A $7.2M clean-energy PO and a $3.6M medical line just doubled the backlog story — yet management still won't raise the full-year number, and a new defense tab is quietly opening.
SOTK · Earnings Call · 2026-10-14
The number that never hit the income statement
Sono-Tek's fiscal H1 FY27 call, delivered two days after the shares had retreated from a fresh high, was built around an item that does not appear in the P&L. Chairman Christopher Coccio opened with the framing everyone was waiting for: “3 orders totaling approximately $7.2 million which covered 10 production scale systems and represent the largest aggregate... order in Sono-Tek's history” — Christopher L. Coccio, Unknown · 2026-10-14. Stack that next to the previously announced medical diagnostic production line (more than $3.6M) and you get over $10.79 million of programs from two different customers in two unrelated end markets — an ultrasonic-coating microcap suddenly holding a backlog that is enormous relative to its ~$81M market cap.
The reported quarter itself was modest by comparison. H1 revenue rose 6% to ~$10.9M, gross profit climbed 14%, and operating income jumped 41%. The latest filed quarter shows the margin engine working: gross margin of 56.8%, up ~4.9pp year over year and operating margin near 15.8%, +6.4pp. Total revenue is up ~77% over ten years — but the growth is lumpy, and cash keeps compounding: effective net cash of ~$8M, up ~192% in four years, now sitting near $17.7M of cash and marketable securities with no debt.
A gap year, by design
Here is the tension worth sitting with. Medical sales exploded +289% to ~$7.1M in H1, backlog rose 23% sequentially, and yet CEO Steve Harshbarger “is reiterating our expectation for flat to modest revenue growth for this current fiscal 27” — R. Stephen Harshbarger, President and CEO · 2026-10-14. That is not a contradiction — it is a timing disclosure. The record clean-energy systems are forecast to ship "primarily during fiscal 28," which is why the last several quarters keep producing multi-million-dollar announcements that land on future revenue lines rather than the current one. Anyone modeling FY27 on order momentum will be disappointed; anyone modeling FY28 has just been handed real visibility.
The setup has a recognizable shape from the prior calls. In May, management described a backlog that had “really transitioned and shifted drastically over to the medical sectors and the microelectronics sectors” — R. Stephen Harshbarger, CEO and President · 2026-05-28 while clean energy went "very light." A year earlier, it had warned that the largest clean-energy orders “will be shipping in our FY 2027 year” — Steve Harshbarger, CEO and President · 2025-10-14. The pattern is now a franchise trait: Sono-Tek books the headlines one fiscal year and recognizes them the next.
Four verticals, one playbook
The mechanism is the interesting part, and it is being reinforced. Harshbarger described a customer that started in R&D and is now expanding: “as that customer has success, the orders keep coming because every production line that they build, you know, we are attached at the hip with them” — R. Stephen Harshbarger, President and CEO · 2026-10-14. That flywheel is staffed by the forward deployed engineer group, which has scaled from one person to four and is slated to double again — a deliberate bet that integration capability pays back in one to two years versus the five to six a new core ultrasonic coating line takes. It is the same story the company has told since a high volume production model emerged in fiscal 2023, now with more money behind it.
What is genuinely new this quarter is defense. The keyword spikes to the top of Sono-Tek's own vocabulary — defense sector — and management does not soft-pedal it: an optics-related shipment to defense was the driver behind a 156% jump in industrial sales, and Harshbarger openly mused about adding a defense "tab" to the website. It is a company-unique theme that never appeared in the prior five Q&A transcripts and has nothing to do with the medical medical market engine that carried H1. Meanwhile alternative energy — the company's identity for years through green hydrogen, fuel cells and solar — has been resurrected from near-death, but reframed as repeat production-line expansion rather than a market recovery.
The tape is voting the other way on semiconductors
Sono-Tek's most ambitious future is microelectronics: a push from 200mm lab tools toward 300mm fab photoresist, and a first-ever appearance at SEMICON Europe. That ambition rides a genuinely hot global theme — the AI CapEx cycle that is pulling capital into advanced chipmaking. But the actual tape disagrees with the timing. Across global semis, high volume production, co-packaged optics and High Bandwidth Memory names are among the largest 90- and 30-day decliners — AI-adjacent hardware has cooled hard even as the capex narrative stays loud. Sono-Tek is leaning into a wave that is structurally intact on a 360-day view and currently cold on a 90-day one. Management even concedes the demand is "an inning or two earlier" than medical or clean energy.
The company's own tape reflects that ambivalence. The stock is up ~26% over the last ~94 trading days, but the as-of close sits ~13% below a fresh high set two days before the call — a sharp pullback into the print. Fundamentals flagged this too: receivables-to-revenue spiked to a peak near 72.5% in the prior quarter before snapping back to ~22%, a swing worth watching given the large, milestone-billed systems now flowing through.
What it adds up to
The bear read is that Sono-Tek is a perpetually-lumpy capital-equipment name with a great balance sheet and no near-term revenue leverage; the bull read is that it has now demonstrated the process four times — medical, clean energy, semiconductor and defense — and the FY28 backlog is real, not aspirational. Management's own word for it is operating leverage: “I gotta believe we are gonna see some significant leverage here at least from this next phase from that $22 million to say $40 million area” — R. Stephen Harshbarger, President and CEO · 2026-10-14. The capacity math supports it — a phased expansion from a ~$27M footprint toward ~$45M and, eventually, an ~$85M plan for the first time.
The honest framing is that this is a story about a company that keeps booking the future and reporting the past. The defense tab is new, the clean-energy resurrection is real, and the medical franchise is quietly becoming the reliability engine. Whether any of it shows up in fiscal 2027 remains an open question — and the guidance says: mostly, it won't.